Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 is involved in cognitive brain function and learning, 98”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [98]
In the citing paper
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85,86,87].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [86]
In the citing paper
“They are involved in multiple biological pathways that could be beneficial in AD including improvement of BBB integrity and vascular health, promotion of homeostasis in microglia and astrocytes, positive effects on adaptative immune cells (including natural killer cells and activated regulatory T cells), improvement of synaptic viability, and neuroprotection [17–26].”
In the citing paper
“Preclinical results in murine models treated with GLP-1RAs suggest that the potential effects of semaglutide in AD may be exerted via impact on several AD-related pathophysiologic processes including neuroinflammatory pathways, vascular and BBB integrity, reduced synaptic loss, and neuroprotection [19, 21, 23–26, 46–48];”
Citations
Cites
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
The molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, GLP-1 exerts effects on glucose-dependent insulin secretion, insulin biosynthesis, gastrointestinal motility, islet b-cell neogenesis, energy homeostasis and food intak”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Immunohistochemical comparison of the CA3 subregion of the hippocampus using Fluorojade-B, a fluorochrome stain specific for degenerating neuron”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationEnvironmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 732
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citation
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Self-citationThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“In rats, central GLP-1R agonism improves several aspects of learning and memory, as demonstrated by improved performance in the Morris water maze test and by enhanced latency in the passive avoidance test [417].”
BackgroundMethodInfluentialSelf-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Potential novel indications: neurodegenerative diseases and psoriasis Interest in using GLP-1 RAs to treat neurodegenerative diseases emerged from preclinical studies showing that GLP-1 receptor signaling is involved in cognitive functions [220] and GLP-1 RAs can induce neuronal growth and synaptic plasticity and redu…”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationBrain foods: The effects of nutrients on brain function.
Gómez-Pinilla, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2421 · Cited by 1,372
“GLP1 receptors are expressed in neurons, and infusion of GLP1 into the brain has been shown to improve associative and spatial memory in rat”
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
“[Ser(2)]exendin(1–9) [76] 980 Da Not determined Facilitated learning; reduced kainic-acid induced apoptosis”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Self-citationExercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models
Lourenco, M. V., Frozza, R. L., de Freitas, G. B., Zhang, H., Kincheski, G. C., Ribeiro, F. C., Gonçalves, R. A., Clarke, J. R., Beckman, D., Staniszewski, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0275-4 · Cited by 935
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Evaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O'Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 713
Characteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
“Intranasal delivery of drugs, including peptides [35], shows a great deal of promise [36].”
Self-citationMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
De Felice, F. G., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 639
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultGlucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationBrubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Self-citationSalvi, P. S., & Cowles, R. A. (2021) · Cells · doi:10.3390/cells10071775 · Cited by 526
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
“Previous studies have shown similar effects in the brain, in particular on cell proliferation and neurogenesis [14,18-21], and our results add considerably to those findings.”
ResultGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
“More surprising are reports that GLP-1 improves memory and learning (2), is cardioprotective during myocardial ischemia (3), promotes hepatocyte function (4), and increases pancreatic exocrine”
BackgroundType 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
Srikanth, V., Sinclair, A. J., Hill-Briggs, F., Moran, C., & Biessels, G. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30118-2 · Cited by 465
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“In addition, they have been shown to enhance synaptic transmission and counteract learning deficits (30, 31).”
BackgroundInfluentialTherapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Self-citationMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Kim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
“[81] DuringMJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al.”
Mutant G-protein-coupled receptors as a cause of human diseases
Schöneberg, T., Schulz, A., Biebermann, H., Hermsdorf, T., Römpler, H., & Sangkuhl, K. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.008 · Cited by 337
Noble, E. E., Hsu, T. M., & Kanoski, S. E. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00009 · Cited by 333
“Importantly, GLP-1 signaling promotes hippocampal neural plasticity and improved memory function (During et al., 2003; McClean et al., 2010; Li et al., 2012).”
BackgroundAlzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Prasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
Dysregulation of insulin receptor substrate 2 in β cells and brain causes obesity and diabetes
Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y., & White, M. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22217 · Cited by 313
“Dysregulation of GLP1 signaling has been reported in type 2 diabetes, which might impair IRS2 expression in β cells and the brain (39, 40).”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Experimental data indicate that GLP-1 may also exert actions in the brain beyond these well-established effects, by influencing neuronal health, cognition and neuroinflammation (During et al. 2003, Li et al. 2009, McClean et al. 2011, Tweedie et al. 2013).”
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Beard, E., Lengacher, S., Dias, S., Magistretti, P. J., & Finsterwald, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.825816 · Cited by 302
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Vaynman, S., & Gomez‐Pinilla, F. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20979 · Cited by 299
“According to the During et al. (2003) study, the intracerebroventrical infusion of GLP-1 or the conserved nine-amino acid N-terminal domain of the protein, Ser(2)exendin (1-9) or the intranasal infusion of Ser(2)exedin (1-9), enhanced associative and spatial memory.”
BackgroundInfluentialKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Li, X., Leng, S., & Song, D. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s74042 · Cited by 292
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Self-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“of fluid and energy homeostasis as well as in the processes of learning and memory [57,131], other, yet”
BackgroundThe role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Kanoski, S. E., & Grill, H. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.011 · Cited by 273
Drucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Self-citationHernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267
“Glucagon-like peptide-1 (GLP-1) exerts neuroprotective effects in both the central and peripheral nervous system (12-14).”
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
“2002a,b) and enhancement of cognitive functions (During et al. 2003).”
InfluentialSalcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 259
Role of metabolism in neurodegenerative disorders
Procaccini, C., Santopaolo, M., Faicchia, D., Colamatteo, A., Formisano, L., de Candia, P., Galgani, M., De Rosa, V., & Matarese, G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.018 · Cited by 258
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationDelivery of interferon-β to the monkey nervous system following intranasal administration
Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D., & Frey, W. H. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.013 · Cited by 242
Hyperglycemia in Acute Ischemic Stroke: A Vascular Perspective
Martini, S. R., & Kent, T. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600355 · Cited by 240
“Interestingly, in animal models GLP-1 can cross the blood–brain barrier (Kastin et al, 2002) and protect neurons against in vitro and in vivo excitotoxicity (Perry et al., 2002; During et al, 2003).”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Common variants at 12q14 and 12q24 are associated with hippocampal volume
Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium, & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (2012) · Nature Genetics · doi:10.1038/ng.2237 · Cited by 232
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
Meredith, M. E., Salameh, T. S., & Banks, W. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9719-7 · Cited by 225
Self-citationNeuronal Apoptosis in Neurodegeneration
Okouchi, M., Ekshyyan, O., Maracine, M., & Aw, T. Y. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1511 · Cited by 218
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
“JCI Insight 2023;8(12):e170671 https://doi.”
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic β Cell Growth and Function
Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G., & White, M. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508307200 · Cited by 208
Nørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12268 · Cited by 206
Bhutada, P., Mundhada, Y., Bansod, K., Tawari, S., Patil, S., Dixit, P., Umathe, S., & Mundhada, D. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.022 · Cited by 205
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats
Pintana, H., Apaijai, N., Chattipakorn, N., & Chattipakorn, S. C. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0521 · Cited by 204
Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 198
Klugmann, M., Wymond Symes, C., Leichtlein, C. B., Klaussner, B. K., Dunning, J., Fong, D., Young, D., & During, M. J. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.10.002 · Cited by 196
Self-citationHeppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191
Kosaraju, J., Gali, C. C., Khatwal, R. B., Dubala, A., Chinni, S., Holsinger, R. M. D., Madhunapantula, V. S. R., Muthureddy Nataraj, S. K., & Basavan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.008 · Cited by 189
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Promoting neuroprotection in many, not necessarily mutually exclusive, ways, specifically by enhancing DNA repair [151]; increasing expression and signaling of brain-derived neurotrophic factor (BDNF) [55, 152, 153]; reducing Aβ oligomers [38], Aβ plaque load [38-40, 154-157], Aβ toxicity [158-162], advanced glycation…”
BackgroundSelf-citationBrain injury with diabetes mellitus: evidence, mechanisms and treatment implications
Hamed, S. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1293521 · Cited by 185
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Self-citationHsu, T. M., Hahn, J. D., Konanur, V. R., Lam, A., & Kanoski, S. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.175 · Cited by 176
Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12088 · Cited by 183
“, 2009), and GLP-1 receptor replacement could reverse that impairment (During et al., 2003), the cognitive improvement effect of vildagliptin (DPP-4 inhibi-”
BackgroundInfluentialPerry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Martin, B., Golden, E., Carlson, O. D., Pistell, P., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W. A., Greig, N. H., et al. (2009) · Diabetes · doi:10.2337/db08-0799 · Cited by 181
Poornima, I., Brown, S. B., Bhashyam, S., Parikh, P., Bolukoglu, H., & Shannon, R. P. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.766402 · Cited by 182
Metadata
- Authors
- During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., & Haile, C. N.
- Affiliations
- University of Auckland (NZ)
- Thomas Jefferson University (US)
- St. Louis VA Medical Center (US)
- University of Toronto (CA)
- Corresponding author
- During, Matthew J
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-08-17
- Volume
- 9
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2124852816
- Cited by
- 851
- References
- 42
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 50 · 2023: 39 · 2022: 58 · 2021: 53 · 2020: 44 · 2019: 36 · 2018: 37 · 2017: 39 · 2016: 34 · 2015: 54 · 2014: 46 · 2013: 47 · 2012: 43
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Marsden Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, associative learning, spatial learning, memory, hippocampus, neuroprotection, kainate-induced seizures, neuronal apoptosis, cognitive enhancement, gut-brain signaling
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Administration, Intranasal, Amino Acid Sequence, Animals, Behavior, Animal, Cognition, Glucagon, Hippocampus, Kainic Acid, Learning, Male, Molecular Sequence Data, Neurons, Peptide Fragments, Protein Precursors, Seizures, Signal Transduction, Gene Expression, Rats, Sprague-Dawley, Apoptosis, Sequence Homology, Amino Acid, Gene Transfer Techniques, Receptors, Glucagon, Mice, Knockout, Neuroprotective Agents, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.